Testing electrical stimulation to slow vision loss from geographic atrophy

Plain-English translation of NCT07531927 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated August 2026 · How we translate trials

This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.

What is this trial?

This study is testing a device called the OkuStim 2 System, which uses gentle electrical stimulation applied to the eye to treat geographic atrophy—a progressive condition where cells in the back of the eye gradually die, causing vision loss. Researchers believe this electrical stimulation may reduce inflammation in the eye and protect remaining healthy cells, potentially slowing vision loss. The trial will compare two different types of electrical stimulation patterns against a placebo (sham) treatment to see which works best and is safest.

Geographic atrophy currently has no approved treatment in Europe, and it causes progressive, irreversible vision loss in older adults. This trial exists to test whether this treatment can slow that vision loss by protecting the healthy cells surrounding the damaged area of the eye.

Do you qualify?

You likely qualify if…

you are 60 years of age or older
you have been diagnosed with geographic atrophy caused by age-related macular degeneration
your geographic atrophy is confirmed by eye imaging and falls within a specific size range
you have at least a minimum level of visual acuity in the study eye
you are willing and able to understand the study and provide informed consent

You likely don't qualify if…

you have had major eye surgery, retinal surgery, or laser treatment in the eye being studied
you have other eye conditions that could interfere with the study, such as swelling of the macula, abnormal blood vessel growth, retinal detachment, or blood vessel blockage
you have active medical implants (such as a pacemaker)
you have a history of epilepsy or serious uncontrolled health conditions that would prevent you from following study procedures
you are pregnant, breastfeeding, or a heavy smoker

What participation looks like

After an initial training phase, you would use the OkuStim 2 device at home once per week for 30 minutes at a time, for a total of 12 months. You will be randomly assigned to receive one of two types of electrical stimulation treatment or a placebo treatment. Throughout the study, you'll have regular check-ups to monitor your vision, take eye images, and track any side effects or changes in your condition.

AI-generated summary from trial data · Aug 1, 2026 · Not medical advice

Testing electrical stimulation to slow vision loss from geographic atrophy

What is this trial?

Do you qualify?

What participation looks like

Trial locations